Aevis Victoria H1 2026 NAV Rises 7% as Healthcare Margins Improve

EarningsCorporate Action
โดย GuruFocus·CH·Read original
Summary · why it matters

Aevis Victoria reported a net asset value of CHF26.75 per share for H1 2026, up nearly 7% year-over-year and 2.3% versus the prior year-end level, while the discount to NAV remained above 50%, which management described as unprecedented in the group's history. Within the healthcare segment, Swiss Medical Network's EBITDA margin improved from 18.6% to 21.6%, and ambulatory services turned EBITDA-positive for the first time, with its margin rising from 7.1% to 11.8%. The company set a healthcare EBITDA margin target of 23% with organic growth of 2% to 3% per year, noting mature hospitals representing over 50% of the portfolio can reach more than 25% to 26% EBITDA margin while ramp-up hospitals sit at 10% to 20%. Interest expenses declined 43% year-over-year, consolidated net debt stood at CHF846 million with the bulk under Swiss Hotel Property, Swiss Medical Network's net debt-to-EBITDA was approximately 2.2x to 2.3x, and loan-to-value for the real estate business fell to 45%. Chief Financial Officer Michel Keusch cited three catalysts to narrow the discount to NAV: a next phase of value crystallization through selling stakes to strategic shareholders, including the officially announced search for strategic investors in Swiss Medical Network; enhanced investor relations with more roadshows, a Capital Markets Day and greater financial transparency; and a near-quintupling of average daily liquidity over the past two years.

Impact on stocks 1

Aging Population▲ · 1 stocks
Aevis Victoria SA
AEVS
▲ PositiveCapitalrelevance

H1 2026 NAV rose ~7% YoY to CHF26.75/share with healthcare EBITDA margin improving to 21.6% and interest expenses down 43%.

Theme Impact 1

Related news

CVS Omnicare Wins Court Approval for Chapter 11 Liquidation

A Texas bankruptcy judge has approved a wind-down Chapter 11 plan for CVS Omnicare, the long-term care pharmacy subsidiary of CVS Health, after the company sold its business operations for $250 million and reached a $440 million settlement with the Justice Department over an improper billing case. Judge Stacey G. C. Jernigan of the U.S. Bankruptcy Court for the Northern District of Texas approved the plan, noting it received overwhelming acceptance from general unsecured creditors. Omnicare, which CVS has owned since 2015 and which serves nursing homes, assisted living centers, and long-term care and rehab facilities, filed for bankruptcy in September 2025, months after a $949 million judgment for fraudulently dispensing drugs without valid prescriptions to elderly and disabled patients. The government resolved that judgment through the $440 million settlement, which requires CVS to pay $130 million upfront and cover the remaining $310 million if Omnicare fails to pay by March 2028. The purchaser, GenieRx Holdings, is a joint partnership between Milrose Capital LLC and Integro Asset Management LLC, and Omnicare attorney Martha Wyrick of Haynes and Boone LLP said the sale is expected to close next month.
AMZNCVS
Aging Population
TheStreet·15hRead more →
▲

Healthpeak Raises 2026 Guidance on Portfolio Sales and Janus Living Growth

Healthpeak Properties raised its full-year 2026 guidance for the second time this year, now expecting diluted earnings per share of $0.48 to $0.52, up from $0.46 to $0.50, and diluted FFO as Adjusted of $1.73 to $1.77, two cents higher at the midpoint than its prior outlook. The healthcare real estate owner signed 1.6 million square feet of new and renewal leases in the quarter, lifting outpatient medical occupancy 20 basis points to 90.7% and lab occupancy 80 basis points to 78.5%. Growth was led by Janus Living, the senior housing operator Healthpeak controls with a 73.6% stake, where revenue jumped 45% year over year to $216 million and Adjusted EBITDA rose 34% to $79 million, with same-store margins expanding 250 basis points. Healthpeak funded buybacks and debt paydown largely by selling stakes in existing buildings, including July's recapitalization that sold a 49% stake in an 86-property outpatient medical portfolio to Brookfield for roughly $1.025 billion at a 5.9% cap rate, part of $1.4 billion of proceeds generated in the quarter and through August 3. Lab same-store net operating income fell 3.2%, the only one of Healthpeak's three core businesses to shrink, holding total company-wide same-store NOI growth to 1.8%.
DOC ▲JAN ▲BAM
Aging Population ▲
Insider Monkey·1dRead more →

Ramsay Santé unveils Connecting Care 2030, targets 3% annual growth by FY2029

Ramsay Santé Group unveiled "Connecting Care 2030," a new four-year strategic roadmap, at its 2026 Capital Markets Day in Paris. The plan targets revenue growth of between 2.0% and 3.0% in FY2027 with a stable EBITDA margin versus FY2026, and revenue growth of approximately 3.0% per annum with gradual EBITDA margin improvement by FY2029, alongside gross capex of about 4.0% of revenue on average over the FY2027 to FY2029 period. The group also targets continued deleveraging, with net debt to EBITDA on a pre-IFRS basis below 4.0x. The strategy rests on five pillars: strengthening the integrated and accessible healthcare offering, embracing digital transformation, active portfolio and contract management, continued cost initiatives, and accelerating profitable growth through new revenue streams. Separately, majority shareholder Ramsay Health Care, which holds 52.79% of Ramsay Santé Group, has announced its intention to distribute its entire stake to its own shareholders through an in-specie distribution expected in December of this year, and Ramsay Santé has applied for a foreign exempt listing on the Australian Securities Exchange through CHESS Depository Interests. Crédit Agricole Assurances, which holds 39.82% of the group, has reaffirmed its commitment as a long-term shareholder.
GDS.PA ▲
Aging Population
Ramsay Santé·2dRead more →
© 2026 MarketDXNews